Investors and analysts will be looking ahead to AbbVie Inc. The stock volatility for week was 2.71% while for month was 1.82%.The stock, as of last close, traded 13.06% to its 52 week low and was changed -17.36% from its 52 week high.
08/08/2016 - AbbVie Inc. had its "buy" rating reiterated by analysts at Argus. They now have a United States dollars 78 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock.
Other Hedge Funds, Including, Welch Group boosted its stake in ABBV in the latest quarter, The investment management firm added 2,384 additional shares and now holds a total of 232,086 shares of AbbVie Inc which is valued at $12,945,757. The consensus rating is 1.6, indicating analysts in general look favorably on the company's future prospects. Leerink Partners Initiated AbbVie Inc on Oct 18, 2016 to "Mkt Perform", Price Target of the shares are set at $70.AbbVie Inc was Downgraded by JP Morgan to " Neutral" on Sep 8, 2016.
AbbVie Inc (NYSE:ABBV) is expected to release the earnings of its current quarter on 10/28/16. The company most recent volume stood at 24.87 million shares as compared to average volume of 6.43 million shares. The company has a market capitalization of $92.85 billion, a P/E ratio of 15.414 and a beta of 1.55. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -9.17% where SMA50 and SMA200 are -11.17% and -6.86% respectively. The stock stands almost -17.36% off versus the 52-week high and 13.06% away from the 52-week low. (NYSE: ABBV) from Outperform to Neutral in a research note to investors today. The business earned $6.43 billion during the quarter, compared to the consensus estimate of $6.55 billion. During the same quarter previous year, the business posted $1.13 EPS.
Something important to note is that because Zacks and Thomson Reuters poll different sets of analysts, their average EPS estimates may differ. The ex-dividend date of this dividend is Wednesday, January 11th. This represents a $2.56 annualized dividend and a dividend yield of 4.44%. AbbVie Inc makes up approx 0.36% of Wagner Bowman Management Corp's portfolio. AbbVie's payout ratio is now 61.62%.
In other news, insider Laura J. Schumacher sold 50,000 shares of the firm's stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $65.00, for a total value of $3,250,000.00. For the current year the company has fixed $25.83B revenues, as per the opinion of 21 analysts. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Following the transaction, the Executive Vice President is left with a stake of 3250 shares, now valued at $187200. Welch Group LLC raised its position in AbbVie by 1.0% in the third quarter. Robeco Institutional Asset Mgmt Bv last reported 1.84M shares in the company. Cypress Capital Management LLC WY purchased a new stake in shares of AbbVie during the second quarter valued at about $114,000. CapWealth Advisors LLC raised its stake in shares of AbbVie by 55.2% in the first quarter. However the company's price to cash per share for most recent quarter stands at 11.45.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company.
Ranger Management Ltd Partnership holds 2.41% of its portfolio in AbbVie Inc (NYSE:ABBV) for 91,910 shares.